Dr. Ching: "Our focus near term is to become EBITDA positive as we re-establish solid fundamentals throughout the organization."
I like the prudence Dr. Ching showed by delaying all PRs until he had thoroughly reviewed HRCT. Dr. Phan has built a sound company, and it appears that Dr. Ching is going to move us energetically forward.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.